Physician profile
Anne Oliphant
NPI 1184060956
$694.80
in general payments reported to CMS, 2019-2025
13 companies · $574 in 2025
The $574 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $289.70 | 2023-2025 | |
| Coopersurgical, INC. | $120.17 | 2025 | Ally II Ups |
| Astellas Pharma US INC | $54.69 | 2025 | Veozah |
| Radius Health, INC. | $40.89 | 2025 | Tymlos |
| Amgen INC. | $37.24 | 2025 | Evenity |
| Millicent US INC | $29.33 | 2025 | Femlyv |
| Biogen, INC. | $26.06 | 2025 | Zurzuvae |
| Meditrina | $20.66 | 2025 | |
| Novo Nordisk INC | $16.76 | 2025 | Wegovy |
| Sumitomo Pharma America, INC. | $16.04 | 2025 | Myfembree |
| Shield Therapeutics INC | $15.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.24 | 2025 | |
| Organon LLC | $13.34 | 2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Oliphant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.